Detalhe da pesquisa
1.
Small molecule mediated inhibition of RORγ-dependent gene expression and autoimmune disease pathology in vivo.
Immunology
; 147(4): 399-413, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26694902
2.
Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
Bioorg Med Chem Lett
; 25(15): 2985-90, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26048789
3.
Discovery of biaryl carboxylamides as potent RORγ inverse agonists.
Bioorg Med Chem Lett
; 25(15): 2991-7, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26048806
4.
Discovery of camphor-derived pyrazolones as 11ß-hydroxysteroid dehydrogenase type 1 inhibitors.
Bioorg Med Chem Lett
; 24(12): 2707-11, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24815509
5.
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
J Exp Med
; 221(3)2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38334978
6.
Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy.
bioRxiv
; 2023 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37609171
7.
MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
Blood Adv
; 5(5): 1388-1402, 2021 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33661300
8.
4-Substituted-7-N-alkyl-N-acetyl 2-aminobenzothiazole amides: drug-like and non-xanthine based A2B adenosine receptor antagonists.
Bioorg Med Chem Lett
; 20(14): 4140-6, 2010 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20541935
9.
The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.
Curr Med Chem
; 14(23): 2471-81, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17979700
10.
Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.
Curr Med Chem
; 13(15): 1839-43, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16787225
11.
Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes.
ACS Med Chem Lett
; 4(4): 414-8, 2013 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900686
12.
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
J Med Chem
; 55(16): 7021-36, 2012 Aug 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-22809456
13.
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
J Med Chem
; 53(9): 3618-25, 2010 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-20405948
14.
Optimization of the beta-aminoester class of factor Xa inhibitors. Part 1: P(4) and side-chain modifications for improved in vitro potency.
Bioorg Med Chem Lett
; 12(12): 1667-70, 2002 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-12039586
15.
Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.
Bioorg Med Chem Lett
; 12(12): 1671-4, 2002 Jun 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-12039587
16.
Allosteric activators of glucokinase: potential role in diabetes therapy.
Science
; 301(5631): 370-3, 2003 Jul 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-12869762
17.
Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity.
Bioorg Med Chem Lett
; 13(17): 2895-8, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14611852